U.S. generics drugmaker Mylan N.V. said on Thursday the U.S. Patent and Trademark Office rejected French pharma company Sanofi's patent infringement claims related to two formulations of its blockbuster insulin drug Lantus.
from Reuters: Health News https://ift.tt/2QO5e4j
via
IFTTT
0 comments:
Post a Comment